Who developed Alprolix?
Who developed Alprolix?
Biogen Idec and Swedish Orphan Biovitrum (Sobi) are partners in the development and commercialization of ALPROLIX for hemophilia B.
When did Eloctate launch?
Development Timeline for Eloctate
| Date | Article |
|---|---|
| Jun 6, 2014 | Approval FDA Approves Eloctate – first Antihemophilic Factor, Fc Fusion Protein for Patients with Hemophilia A |
What is Alprolix made of?
ALPROLIX is a recombinant, fusion protein that temporarily replaces the missing coagulation Factor IX needed for effective hemostasis. ALPROLIX contains the Fc region of human IgG1, which binds to the neonatal Fc receptor (FcRn).
What is hemophilia B?
Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Without enough factor IX, the blood cannot clot properly to control bleeding.
What is Alprolix used for?
This medication is used to prevent or control bleeding in people with little or no factor IX (due to hemophilia B, Christmas disease). Factor IX is a protein (clotting factor) in the blood that works with other clotting factors to help the blood clot and stop bleeding.
What is the half life of Alprolix?
For the factor IX Fc, now called Alprolix, we’ve been able to achieve a half-life of about 82 hours, or about three and a half days.
Who owns Eloctate?
Sanofi picked up Eloctate in last year’s $11.6 billion buyout of hemophilia-focused Bioverativ. The deal was one of several moves by the French drugmaker intended to shift the company away from a reliance on primary care and bring it further into rare diseases.
Who developed Eloctate?
The drug is developed and marketed by Biogen Idec in collaboration with Swedish Orphan Biovitrum (Sobi). In June 2014, the US Food and Drug Administration’s (FDA) approved Eloctate for control and prevention of bleeding episodes during surgeries and routine prophylaxis in haemophilia A-affected patients.
What is the half-life of Alprolix?
What are the 3 types of hemophilia?
The three main forms of hemophilia include the following:
- Hemophilia A: Caused by a lack of the blood clotting factor VIII; approximately 85% of hemophiliacs have type A disease.
- Hemophilia B: Caused by a deficiency of factor IX.
- Hemophilia C: Some doctors use this term to refer to a lack of clotting factor XI.
Who manufactures advate?
Takeda has a variety of resources to help you and your patient navigate access to ADVATE.
